Neue Therapieansätze bei chronischer Insomnie

Die Insomnie stellt eines der häufigsten Krankheitsbilder mit weitreichenden gesundheitlichen und sozioökonomischen Folgen dar. Nach längerer Stagnation konnten in den letzten Jahren wieder vielversprechende Fortschritte in der nichtpharmakologischen und pharmakologischen Behandlung von Patienten mit chronischer Insomnie verzeichnet werden. Der Artikel beleuchtet diese neuen Therapieansätze im Kontext etablierter Behandlungsmöglichkeiten.

Abstract

Insomnia represents one of the most common syndromes with far-reaching health and socioeconomic consequences. After a long period of stagnation, recent years have seen promising advances in the nonpharmacological and pharmacological treatment of patients with chronic insomnia. This article highlights these new therapeutic approaches in the context of established treatment options.

Schlüsselwörter

Schlafstörung - Kognitive Verhaltenstherapie - digitale Gesundheitsanwendung - Hypnotika - Orexin

Key word

Sleep disorder - cognitive behavioral therapy - digital health - hypnotics - orexin

Publication History

Article published online:
17 October 2023

• Literatur

• 1 Riemann D, Baum E, Cohrs S. et al. S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen – Kapitel „Insomnie bei Erwachsenen“, Update. 2016 2017.
• 2 Schlack R, Hapke U, Maske U. et al. Häufigkeit und Verteilung von Schlaf-problemen und Insomnie in der deutschen Erwachsenenbevölkerung. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2013; 5: 740-748
• 3 Léger D, Guilleminault C, Bader G. et al. Medical and socioprofessional impact of insomnia. Sleep 2002; 25: 621-625
• 4 Porwal A, Yadav YC, Pathak K. et al. An update on assessment, therapeutic management, and patents on insomnia. Biomed Res Int 2021;
• 5 Weinhold SL, Göder R. Kognitive Verhaltenstherapie bei Insomnie. Somnologie 2022; 26
• 6 Edinger JD, Arnedt JT, Bertisch SM. et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: An American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. Journal of Clinical Sleep Medicine 2021; 17
• 7 Alonzo R, Hussain J, Stranges S. et al. Interplay between social media use, sleep quality, and mental health in youth: A systematic review. Sleep Med Rev 2021; 56
• 8 Lorenz N, Heim E, Roetger A. et al. Randomized controlled trial to test the efficacy of an unguided online intervention with automated feedback for the treatment of insomnia. Behavioural and Cognitive Psychotherapy 2019; 47
• 9 Mayer G. S2k-Leitlinie: Insomnie bei neurologischen Erkrankungen. DG Neurologie 2020; 3
• 10 Brandt MD. Insomnie im Rahmen neurologischer Erkrankungen. Fortschr Neurol Psychiat 2021; 89
• 11 vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharmacists Assoc 2012; 52
• 12 de Crescenzo F, D’Alò GL, Ostinelli EG. et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet 2022; 16: 170-184
• 13 Huedo-Medina TB, Kirsch I, Middlemass J. et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: Meta-analysis of data submitted to the Food and Drug Administration. BMJ (Online) 2013; 346
• 14 Roehrs TA, Randall S, Harris E. et al. Twelve months of nightly zolpidem does not lead to dose escalation: A prospective placebo-controlled study. Sleep 2011; 34
• 15 Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: A prospective placebo-controlled study. Sleep 2012; 35
• 16 Roth T, Walsh JK, Krystal A. et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6
• 17 Mignot E, Mayleben D, Fietze I. et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebocontrolled, phase 3 trials. Lancet Neurol 2022; 21
• 18 Ufer M, Kelsh D, Schoedel KA. et al. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 2022; 45
• 19 Fietze I, Bassetti C, Mayleben D. et al. Effects of daridorexant on sleep and daytime functioning in older adults with insomnia. Am J Geriat Psychiat 2022; 30